Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b

• Published in: Gut and liver 2018, 12(2), , pp.201-207
• Main Authors: Chida, Takeshi, Kawata, Kazuhito, Ohta, Kazuyoshi, Matsunaga, Erika, Ito, Jun, Shimoyama, Shin, Yamazaki, Satoru, Noritake, Hidenao, Suzuki, Tetsuro, Suda, Takafumi, Kobayashi, Yoshimasa
• Format: Article
• Language: English
• Subjects: Aged; Antiviral Agents - administration & dosage; apolipoproteins; Carbamates; Cohort Studies; disturbed lipid metabolism; Drug Monitoring - methods; Drug Therapy, Combination - methods; Female; Hepacivirus - genetics; hepatitis c virus infection; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - epidemiology; Hepatitis C, Chronic - virology; Humans; Imidazoles - administration & dosage; Isoquinolines - administration & dosage; Japan - epidemiology; Lipid Metabolism - drug effects; Lipoproteins - blood; Male; Middle Aged; Original; Pyrrolidines; Retrospective Studies; Sulfonamides - administration & dosage; Valine - analogs & derivatives; 내과학
• ISSN: 1976-2283; 2005-1212
• DOI: 10.5009/gnl17179

Changes in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years. However, the clinical aspects of disturbed lipid metabolism in chronic HCV infection have not been fully elucidated. Dynamic changes in serum total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and apolipoprotein levels in patients infected with HCV genotype 1b were examined during combination therapy with daclatasvir (DCV) and asunaprevir (ASV). Total, LDL-, and HDL-cholesterol levels increased rapidly and persistently after week 4. Apolipoprotein (apo) A-I, apo B, apo C-II, and apo C-III levels were significantly higher at week 4 than at week 0. In contrast, apo A-II and apo E levels were significantly lower. The differences in LDL- and HDL-cholesterol levels were positively correlated with those of apo B and apo A-I, respectively. Interestingly, in patients with non-sustained virological response, these cholesterol levels decreased rapidly after viral breakthrough or viral relapse. Furthermore, similar changes were observed for apo A-I, apo B and apo C-III levels. Clearance of HCV using combination therapy with DCV and ASV results in rapid changes in serum lipid profiles, suggesting an influence of HCV infection on disturbed lipid metabolism.